食管鳞癌新辅助化疗的研究进展

【摘要】

我国是全世界食管癌高发国家,95%为食管鳞癌。外科手术是治疗食管鳞癌的主要手段,但单纯手术对局部晚期食管鳞癌患者疗效较差。与术后辅助治疗比较,新辅助治疗可使食管鳞癌患者肿瘤体积缩小,提高手术切除率,消灭亚临床远处转移灶,可能延长患者生存时间、改善预后。笔者结合近年循证医学证据,对食管鳞癌新辅助化疗的研究进展进行综述。

【Abstract】

China is a high risk region of esophageal cancer in the world, and 95% of the esophageal cancer is the squamous cell carcinoma. Surgery is the main therapy for esophageal squamous cell carcinoma, however, the efficacy of single surgery for locally advanced esophageal squamous cell carcinoma is unsatisfactory. Compared with postoperative adjuvant treatment, neoadjuvant chemotherapy may reduce tumor volume, increase surgical resectability, eliminate subclinical metastases, prolong survival time and improve prognosis of patients with esophageal squamous cell carcinoma. Through combining recent evidence-based medicine, the authors review research progress of new adjuvant chemotherapy for esophageal squamous cell carcinoma.

展开阅读全文
我还没有学会写个人说明!
上一篇

荧光法与膨胀萎陷法在胸腔镜解剖性肺段切除术中界定段间平面的对照研究

下一篇

食管癌新辅助治疗时代关于病理反应 预测与食管保留策略的思考

你也可能喜欢

发表评论

插入图片
返回顶部

微信扫一扫

微信扫一扫